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ABSTRACT 
Objective 
To investigate the relationship between intestinal inflammation and the central and peripheral 
innate immune system, in the pathogenesis of HLA-B27 associated spondyloarthritis. 
Methods 
The myeloid compartment of the bone marrow and blood of HLA-B27 transgenic (B27), 
control HLA-B7 transgenic (B7), and non-transgenic rats were evaluated by flow cytometry. 
Plasma from rats were assessed by ELISA for CCL2 and IL-1α levels. Rats were treated for 
4 weeks with antibiotics and the blood and bone marrow myeloid compartments were 
evaluated by flow cytometry. The osteoclastogenic potential of bone marrow cells from 
antibiotic treated rats, in the presence or absence of TNFα, was evaluated in vitro. 
Results  
B27 rats have substantially higher numbers of circulating Lin
-
CD172a
+
CD43
lo
 monocytes 
than control animals, which significantly correlates with higher levels of plasma CCL2. 
Antibiotic treatment of B27 rats markedly reduced ileitis, plasma CCL2 and IL-1α levels, 
and the number of bone marrow and blood Lin
-
CD172a
+
CD43
lo
 monocytes, which have the 
greatest in vitro osteoclastogenic potential. Antibiotic treatment also prevented the TNFα-
dependent enhancement of osteoclastogenesis in transgenic B27 rats. 
Conclusions 
The microbiota-dependent intestinal inflammation in B27 rats directly drives the systemic 
inflammatory and bone erosive potential of the monocyte compartment.  
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Introduction 
The HLA-B27 allele of MHC class I (B27) is a major risk factor for the development of 
human spondyloarthritis (SpA), however, its exact contribution to disease enhancement is 
poorly understood. Transgenic rats that express the human HLA-B27 and β2-microglobulin 
genes (B27 rats) develop multi-systemic inflammation that resembles the human SpA clinical 
spectrum(1,2). Inflammation in B27 rats starts in the intestine, with ileitis occurring before 10 
weeks of age, followed by arthritis, psoriasis, and nail dystrophy(2). A link between gut 
pathology and peripheral symptoms has been known for decades, as animals raised in germ-
free conditions develop neither colitis nor arthritis(3). There has been renewed interest in the 
intestinal environment and its contribution to the development of B27-associated pathology. 
It is now evident that the intestinal microbiome in B27 rats is profoundly different from that 
of healthy animals(4).  Importantly, the development of gut pathology in B27 rats is 
associated with specific strains of commensal bacteria (i.e., Bacteroides vulgatus), which can 
be manipulated by oral antibiotic treatment(5,6). The impact of microbial dysbiosis on the 
central and systemic immune system, and the subsequent effect of this on disease 
development is currently under investigation. Recent work in mice has shown that acute T. 
gondii-driven intestinal inflammation can trigger changes in the bone marrow (BM) 
compartment, specifically BM monocyte precursor cells; fundamentally altering their 
function once they migrate into infected mucosal tissue(7). Interestingly, B27 animals lack 
MHC class II
+
 CD103
+
CD172a
low
 migrating dendritic cells, which are involved in controlling 
intestinal immune responses(8). Furthermore, osteoclast pre-cursors in B27 rats have 
enhanced differentiation in response to TNFα compared to control animals, which contributes 
to the B27-associated bone loss(9). It still remains to be determined, however, how changes 
in the myeloid compartment, and B27-associated microbial dysbiosis, affect the central and 
peripheral myeloid compartments, and the osteoclast they mature into. 
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Herein, we have characterised monocyte populations in B27 rats and investigated the effects 
of oral antibiotics on both intestinal pathology and the myeloid compartment. We have 
revealed close correlations between gut pathology and monocyte distribution and showed 
how the latter could directly contribute to B27-associated bone loss.  
 
Materials and Methods 
Animal studies. 
Heterozygous B27 and B7 PVG rats were bred under license as previously described(3,8), 
maintained under specific pathogen–free conditions at the University of Glasgow, and used 
under licenses issued by the UK Home Office. All rats were used between 10-18 weeks of 
age. 
In vivo antibiotic treatment. 
Rats between 10-14 weeks of age were given 50mg/kg/day of Vancomycin and 2.5mg/kg/day 
of Ampicillin/Metranidazole/Neomycin re-suspended in filtered sterile drinking water. 
Administration was by gavage daily on weekdays for 4 consecutive weeks (ABX treated 
group). Equal volume of sterile drinking water was given to control rats (CTRL). Blood was 
sampled twice a week from the tail vein and plasma stored. At day 26, animals were culled 
and blood, hind limbs and gut were harvested for downstream analysis.  
Flow cytometry. 
The white cell fraction of fresh isolated rat BM and blood was obtained by lysis of red cells 
using ACK lysing buffer (Life Technologies), and stained with fluorochrome-labelled 
antibodies and/or with biotinylated antibodies and fluorochrome-labelled streptavidin. 
Briefly, Fcγ receptor was blocked using purified mouse anti-rat CD32 (D34-485; BD 
Biosciences) and cells were stained with biotinylated mouse anti-rat Ig κ, CD90 (OX-6), 
CD45RA (OX-33), and brilliant violet 605
TM
 (BV650) Streptavidin (BioLegend). Monocytes 
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were identified using PE-CD172a (OX-41; BioLegend), APC-CD43 (W3/13; BioLegend), 
V450 or FITC-CD11b (WT.5; BD Biosciences). A DAPI solution (4',6-diamidino-2-
phenylindole; Sigma-Aldrich) was used for live/dead cell exclusion. Cells were acquired 
using an LSRII analyser (BD Biosciences) and data analysed using FlowJo software (Tree 
Star).   
Flow cytometry sorting of bone marrow cells.  
Fluorescent-labelled cells were acquired and sorted using an Aria I sorter and a 70µm nozzle 
(BD Bioscience). Cells were sorted into tubes containing complete α-MEM media 
(supplemented with 10% FBS, 0,02 mM L-glutamine, 10 U/ml Penicillin, and 0.1 µg/ml 
Streptomycin; Invitrogen, Thermo Fisher Scientific) and kept a 4ºC till sorting completion. 
Purity of post-sorting test showed purity ≥ 96%. Sorted cells were seeded in 96 well plates at 
1x10
6
 cells/ml and incubated overnight with 50 ng/ml M-CSF (PeproTech). On day 1, cells 
were stimulated with 50 ng/ml RANK-L (PeproTech). Medium was refreshed on day 4 and 
on day 6-7 cells were fixed and stained for tartrate-resistant acid phosphatase (TRAP) using 
the Acid Phosphatase TRAP kit, following the manufacturer’s instructions (Sigma-Aldrich). 
Four representative images were acquired per well at 10X magnification using an EVOS
®
 FL 
Auto Cell Imaging System (Life Technologies). Osteoclasts were identified as TRAP
+
 
(purple) cells with ≥3 nuclei and counted using Fiji software (Image J).  
Uptake of fluorescent CCL2.  
The fluorescent uptake of CCL2 toward CCR2 receptor was measured using Site-specific 
AF647® labelled chemokine purchased from ALMAC Group LTD, as previously 
described(10). Briefly, fresh primary cells were incubated at 37°C for 1h with 25 nM 
CCL2
AF647
. Cells were then washed and stained for surface marker expression for flow 
cytometry.  
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Chemotaxis assay.  
BM was collected from age-matched B7 and B27 rats. BM cells (BMCs) were suspended at 
5x10
6
 cells/ml in chemotaxis buffer (Dulbecco modified essential medium (DMEM) 
supplemented with 0.5% BSA; Life technology, Thermo Fisher Scientific) and 100 µl of the 
cell suspension was placed onto the top section of a bare filter trans-well (6.5 mm diameter) 
with 5 µm pore size (Corning, UK). Rat CCL2 (0, 10, 100 and 1000 ng/ml) was used as a 
chemo-attractant in the bottom section of the trans-wells (PeproTech). After 3 hours of 
incubation at 37ºC, trans-migration was assessed by counting the cells that had migrated into 
the bottom section of the well. Transmigrated cells were further collected and stained for 
flow cytometry.  
Enzyme-linked immunosorbent assay (ELISA) 
Blood was collected in heparinised tubes and plasma stored; rat CCL2 and IL-1α were 
measured by ELISA following the manufacturer’s instructions (BioLegend and Thermo 
Fisher Scientific respectively).  
Rat bone marrow-derived monocyte collection and osteoclastogenesis.  
Briefly, BM was flushed from long bones and red cells lysed with ACK lysing buffer (Life 
Technologies). BMCs were cultured at 1x10
6
 cells/ml in α-MEM media (supplemented with 
10% FBS, 0,02 mM L-glutamine, 10 U/ml Penicillin, and 0.1 µg/ml Streptomycin; 
Invitrogen, Thermo Fisher Scientific) in the presence of 2.5 mM β-glycerophosphate and 0.05 
mg/ml L-Ascorbic Acid (Sigma-Aldrich) for 2 days. After incubation, non-adherent BMCs 
(NA-BMCs) were collected, seeded at 2x10
5
 cells/well in 96 well plates, and cultured in 
triplicate in the presence of 50 ng/ml M-CSF, 10 ng/ml RANK-L, and 50 ng/ml TNFα 
(PeproTech). Medium was refreshed on day 4 and on day 5 cells were fixed, stained for 
TRAP, and osteoclast quantified, as described above.  
7Rat gut: tissue processing, haematoxylin and eosin staining, and analysis 
Several pieces of the ileum were collected from rats under terminal anaesthesia (4 atm 
Isoflourane and 4 atm O2) and fixed in 4% neutral buffered formalin. Samples were 
dehydrated via increasing concentrations of ethanol and embedded in paraffin wax blocks. 
Transversal and cross sections were cut at 5 µm using a microtome and stained for 
haematoxylin and eosin and mounted with DPX mountant (Sigma-Aldrich Chemical Co.). 
Stained sections were imaged using an EVOS® FL Auto Cell Imaging System (Life 
Technologies) with a 10X objective. Villi and crypt length were measured using a Fiji 
software (ImageJ). 
Statistical analysis 
Prism 6 (Graphpad) was used to perform all statistical analysis and statistical tests used are 
indicated in the figure legends. For all statistical analysis, p-values of ≤0.05 were considered 
significant.  
 
Results 
B27 rats have an altered myeloid compartment with increased CD43
lo
 monocytes  
Rat monocytes (MOs) within the blood and BM(11,12) were identified as lin
- 
(Igκ
-
CD90
-
OX-
33
-
) SSC
lo
CD172a
hi
 and sub-divided by expression of CD43 (Supplemental Figure 1). As 
previously reported(11), the majority of circulating MOs in healthy WT rats were CD43
hi
 
(75.3±7.0%). B27 rats had a significantly altered ratio of CD43
lo
:CD43
hi
 MOs; with 
44.2±12.7% CD43
lo
 and only 54.0±11.5% CD43
hi
 (Figure 1A-B). This change corresponded 
with a substantially higher number of circulating CD43
lo
 MOs in B27 animals (Figure 1C). 
Interestingly, CD43
hi
 MO numbers were not significantly affected in B27 rats (Figure 1C). 
This increased representation of CD43
lo
 MOs was also observed within the BM of B27 rats 
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when compared to WT and B7 transgenic controls (Figure 1D-F). Importantly, no differences 
were evident between WT and the B7 transgenic controls (Figure 1).  
Antibiotics reduce the number of circulating CD43
lo
 monocytes by restoring CCL2 plasma 
levels and reducing BM pre-cursor numbers. 
Oral antibiotics are effective at attenuating signs of ileitis in B27 rats(6). Using broad-
spectrum antibody treatment, we ameliorated B27-associated gut inflammation; as 
determined by reduced ileitis after 4 weeks of oral administration (Figure 2A-B). 
Surprisingly, this was associated with a reduction in CD43
lo
 MOs not only within the 
bloodstream but also within the BM of B27 rats (Fig. 2C-F). This antibiotic-induced 
modulation of monocyte composition did not occur in control animals; as treated and un-
treated non-transgenic animals had comparable numbers of MOs.  
Rat CD43
lo
 MOs express CCR2(11), which is a key chemokine receptor involved in 
monocyte migration from the BM into the bloodstream and recruitment into inflamed tissues. 
We confirmed CCR2 expression in CD43
lo
 MOs using fluorescently-labelled CCL2 (Figure 
3A) and migration towards CCL2 (Figure 3B). Additionally, we observed significantly higher 
CCL2 plasma levels in B27 rats compared to controls (Figure 3C). These data indicate that 
there may be CCL2-dependent altered migration/recruitment of MOs in B27-associated 
diseases. This is supported by a significant positive correlation between CCL2 plasma levels 
and the number of circulating CD43
lo
 MOs in B27 rats (Figure 3D). Moreover, administration 
of antibiotics to B27 rats significantly decreased the plasma levels of CCL2 (Figure 3E). 
Remarkably, one week after initiation of antibiotics, plasma CCL2 in B27 rats returned to 
levels similar to WT controls (Figure 3E). Furthermore, we evaluated whether or not the 
antibiotic treatment affected systemic cytokines in B27 rats. TNFα is known to be highly 
linked to B27-associated disease, however, it was undetectable in both plasma and serum 
(data not shown). In contrast, the level of IL-1α (a potent pro-inflammatory cytokine often 
9associated with TNFα activity) was significantly higher in the plasma of B27 rats compared 
to controls (Figure 3F). Notably, IL-1α plasma levels in B27 rats substantially decreased 
following antibiotic treatment (Figure 3G). These data indicate that oral antibiotics not only 
reduces local inflammation in the gut but also have an impact on systemic inflammation by 
reducing circulating levels of IL-1α, CCL2, and CD43
lo
 MOs.  
Oral antibiotic treatment re-establishes normal responsiveness to TNFα within the BM pre-
osteoclast compartment of B27 rats 
Recent studies have shown that murine monocyte sub-populations have different 
osteoclastogenic potential(13). Evaluation of the osteoclastogenic potential of each of the rat 
BM monocyte populations revealed that the CD43
lo
 MO population contains the main 
osteoclast pre-cursors (Figure 4). Therefore, the observed increase in this population in B27 
rats could contribute to the overt bone pathology observed in these animals as they age. 
Furthermore, it has been demonstrated that BM pre-cursors from B27 rats undergo enhanced 
TNFα-driven (but not RANK-L) osteoclastogenesis compared to controls(9) (Supplemental 
Figure 2). Moreover, the TNFα-enhancement of OC differentiation in B27 rats has been 
associated with IL-1α production and activity(9), which is reduced in the plasma of B27 
animals upon treatment with oral antibiotics (Figure 3F). Importantly, the restoration of 
homeostasis within the monocyte compartment in B27 BM after antibiotics (Figure 2) also 
reversed the TNFα-dependent enhancement of osteoclast differentiation in these animals 
(Figure 5). Thus, treatment of B27 rats with oral antibiotics not only resolves their 
microbiota-dependent intestinal inflammation, but also reduced the levels of circulating 
CCL2, restored homeostasis to blood and BM MOs, and reversed defects in osteoclasts 
generated from these monocytes. 
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Discussion 
It is becoming increasing apparent that the microbial environment within the gut is relevant 
to not only intestinal pathologies but also rheumatic diseases (i.e., RA and AS)(14). Over-
expression of HLA-B27 and β2-microglobulin in rats leads to multi-systemic SpA-like 
inflammation that starts within the gut(1) and is associated with intestinal dysbiosis in early 
stages of disease development(4,15). These animals provide a model to examine mechanisms 
of microbial-mediated systemic inflammation and bone disease, which are also observed in 
HLA-B27
+
 axSpA patients who are often reported to have subclinical intestinal 
inflammation(16). 
Intestinal inflammation in B27 animals leads to increased systemic levels of CCL2; 
this is associated with higher numbers of CCR2
+
CD43
lo
 MOs in both the BM and peripheral 
blood. The CCL2/CCR2 interaction is known to regulate monocyte release from the BM, 
where they are generated, into the bloodstream(17). Perturbation of both CCL2 and CCR2 
has been associated with impaired emigration of BM-MOs into the bloodstream and thus 
lower numbers of circulating ‘classical’ CCR2
+
 MOs in steady-state and during 
inflammation(18,19). How peripheral inflammation can lead to increased CCL2 production 
and monocyte recruitment is still under debate. However, it is known that low concentrations 
of TLR ligands in the blood induce CCL2 production within the BM, which corresponded to 
an enhanced migration of CCR2
+
 MOs into the bloodstream(20). Thus, an increase in the 
amounts of microbial molecules absorbed across the intestinal barrier might contribute to the 
initiation and progression of inflammatory responses. We, therefore, suggest that intestinal 
inflammation in B27 rats can facilitate the dysregulation of the monocyte compartment by 
inducing increased CCL2 expression during the development and perpetuation of disease. 
This is supported by the fact that antibiotic treatment not only reduces the B27 intestinal 
inflammation but also normalises CCL2 levels and monocyte frequencies. Interestingly, 
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‘classical’ MOs are generated within the BM and when released into the bloodstream they 
represent an obligatory intermediate state for the differentiation of ‘patrolling’ MOs(11,21). 
We observed a disconnect in this normal process in the B27 rats, with higher levels of 
‘classical’ CD43
lo
 MOs that persist in both the central (BM) and peripheral compartment. The 
observed changes in MOs in B27 rats have important implications for bone disease as we 
have demonstrated that the CD43
lo
 MOs are the major pre-cursors for osteoclasts in rats. 
Furthermore, our data are consistent with the recent observation that B27 rats have 
pronounced increased osteoclastogenic potential only in the presence of TNFα(9). These data 
taken together may indicate that the B27-osteoclast phenotype directly results from an 
increase in the frequency of the CD43
lo
 MO pre-cursors in B27 animals. This interpretation is 
supported by the fact that antibiotic treatment reduces intestinal inflammation, systemic 
CCL2 levels, numbers of BM and circulating CD43
lo
 MOs, and reverses the B27-associated 
TNFα enhanced osteoclastogenesis. Interestingly, previous studies have shown that anti-
TNFα treatment can inhibit both intestinal inflammation and enthesitis in the peripheral joints 
of B27 animals(22), however, the impact on CD43
lo
 MO pre-cursors was not evaluated. It 
would therefore be interesting to determine whether or not anti-TNFα treatment recapitulates 
those changes seen with antibiotic treatment. 
One limitation of our study is that we were not been able to show the in vivo 
consequences of antibiotic treatment on bone pathology. However, it is important to note that 
the B27 rats used in this study were not old enough to show overt signs of bone pathology. 
This includes no observable changes in circulating bone turnover markers (i.e., collagen type 
1 cross-linked C-telopeptide and procollagen type 1 N-terminal propeptide), osteoclast 
number at bone surfaces, or bone architecture via microCT (data not shown). Studies in our 
laboratory have only been able to detect increased osteoclast numbers at bone surfaces and 
changes in bone architecture in B27 rats that are a minimum of 36 weeks old (data not 
John Wiley & Sons
This article is protected by copyright. All rights reserved.
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shown). Thus, further studies are required to evaluate the long-term impact of antibiotic 
treatment on bone pathology in this model. 
In terms of human disease, alteration in the peripheral monocyte pool has also been 
found in axSpA patients. These patients have higher frequencies of classical CD14
hi
CD16
-
 
monocytes, which correspond to the CD43
lo
 monocytes in the rat. This higher frequency of 
classical monocytes has been associated with spontaneous and elevated production of pro-
inflammatory cytokines in axSpA patients under conventional therapy but not under anti-
TNFα biologics, and this also correlated with BASDAI(23). Together these data support a 
direct and important role of classical monocytes in disease progression. However, further 
studies are still needed to assess the interaction between gut inflammation, the myeloid 
compartment, and the resulting clinical disease. Recent studies have also started to address 
dysbiosis in rheumatic diseases; revealing alteration in the intestinal microbiome in early 
RA(24-25), axSpA(26-27), and PsA(28). However, once again more work is required to 
understand the impact of intestinal perturbation on systemic pathology in remote sites such as 
the joints and bone. Notably, recent studies have shown that gut dysbiosis in PsA patients 
correlates with a lower concentration of medium-chain fatty acids (MCFAs) and RANK-L, 
which have protective effects in maintaining the mucosal integrity and promoting DC/OC 
differentiation in the intestinal lumen respectively(28). Supporting the concept that there is a 
potential link between gut dysbiosis/inflammation and the osteoclast compartment in PsA 
patients.  
In conclusion, we have shown that modulation of the intestinal microbiota in an 
animal model of axSpA not only has wide-ranging effects on systemic inflammatory cells 
and soluble mediators, but also on osteoclastogenesis. This raises the possibility that 
manipulation of the intestinal microbiota in patients with axSpA may provide clinical 
benefits by restoring homeostasis to both the immune and skeletal systems.  
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Figure Legends: 
Figure 1. B27 rats have increased CD43
lo
 monocytes in the bone marrow and blood. (A-
F) The white fraction of cells was collected from WT, B7, and B27 blood and bone marrow 
(BM) and analysed via flow cytometry. (A) Representative density plots showing the 
expression of CD11b and CD43 of circulating blood monocytes (MOs; lin
-
SSC
lo
CD172a
+
) in 
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WT and B27 animals. The experiment was repeated 3 times for a total of n=6 for each group; 
in (B) the percentage and in (C) the absolute numbers of CD43
lo
 and CD43
hi
 in WT, B7 and 
B27 determined. (D) BM was collected from WT, B7 and B27 rats and analysed for the 
expression of CD172a and CD43. Representative density plots show the distribution of BM 
MOs in B7 and B27 rats. (E) Percentages and (F) absolute numbers of the MO subsets in WT, 
B7 and B27 animals. Numbers were calculated from three different experiments pooled 
together for a total of n=5 for WT and n=6 for B7 and B27. Data were analysed using 2-way 
ANOVA with Tukey’s multiple comparisons test. *=P<0.05; **=P≤0.005. ***= P≤0.001. 
****= P≤0.0001. 
 
Figure 2. Antibiotics reduce ileitis and re-establish normal levels of CD43
lo
 monocytes in 
B27 animals. (A-F) B27 and WT animals received 4 weeks of antibiotics (ABX) or water 
(vehicle control, CTRL) and at day 26 the blood white cell fraction and bone marrow cells 
(BMCs) were collected and stained for flow cytometry. (A) Representative H&E staining 
sections of the ileum of ABX and water-treated (CTRL) WT or B27 rats. Tissue sections 
were visualised and digital images captured using an EVOS FL Auto Cell Imaging System 
with a 10X objective. Scale bars = 400 µm. (B) Quantification of villus to crypt ratio. For 
each sample the average of the length of villus and crypt was calculated on 2 different tissue 
sections. Error bars show mean ± SD of n=3-4 for ABX and n=2-3 for CTRL. (C) 
Representative flow cytometry plots showing the monocyte gating in CTRL and ABX within 
the blood. (D) Quantification of circulating CD43
lo
 and CD43
hi
 MOs in B27 and WT rats 
receiving ABX or water (CTRL). (E) Representative dot plots show the BM monocyte 
populations in CTRL and ABX B27 rats. (F) Quantification of CD43
lo
 and CD43
hi
 subsets. 
(D&F) Numbers were calculated from 3 different experiments pooled together using B27 
(n=9 for B27-CTRL and n=12 for B27-ABX) and one experiment using WT rats (n=3). Data 
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were analysed using Kruskal-Wallis test with Dunn’s post hoc test in (B) and one-way 
ANOVA in (D&F) with Sidak’s multiple comparison test. *=P≤0.05; **=P≤0.005; 
***=P≤0.0005. 
 
Figure 3. Antibiotics reduce CCL2 plasma levels in B27 rats. (A-B) CD43
lo
 monocytes 
uptake CCL2 and efficiently migrate toward CCL2 gradient. (A) Blood and BM cells were 
collected from WT rats, incubated with CCL2
AF647
 followed by staining for surface marker 
expression and flow cytometry analysis. The representative histograms show CCL2
AF647 
fluorescence of CD43
lo
 and CD43
hi
 MO subsets in blood and BM. The experiment used 3 
different animals and showed comparable results. (B) BM was collected from a WT animal 
and total BMCs were placed in the top section of a bare filter trans-well. Increasing 
concentrations of recombinant rat CCL2 were used as chemo-attractant in the bottom section 
of the trans-wells. After 3 hours, trans-migrated cells were collected, stained and quantified 
via flow cytometry. Data were analysed with 2-way ANOVA and Dunnett’s post-hoc test 
comparing each data set to the 0 ng/ml values. Data shown are from 1 experiment performed 
in triplicate. Bars show mean ± SD. *= P≤0.05; **= P≤0.01; ****= P≤0.0001. (C) Plasma 
was collected from B7 and B27 animals and CCL2 plasma levels quantified by ELISA. Data 
were analysed with Mann Whitney test. *= P≤0.05; n=6 for both B7 and B27 samples. (D) 
Blood from B27 animals receiving the vehicle (CTRL) was collected twice a week for 4 
weeks; numbers of CD43
lo
 and CCL2 plasma levels were measured for each sample. Samples 
were collected from 2 different experiments and results pooled. Correlation analysis was 
performed using Pearson r test. n=50. (E) Plasma was collected at different time points (day 1 
to 26) from B27 and WT rats treated with ABX or water (CTRL) and CCL2 measured by 
ELISA. Plasma CCL2 of 3 different experiments pooled together in B27 rats and 1 
experiment using WT. Error bars shown mean ± SD. In B27-CTRL n=9; in B27-ABX n=12; 
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in WT-CTRL n=3; in WT-ABX n=3. Data were analysed using 2-way ANOVA and Sidak’s 
multiple comparison test for repeated measure. *=P≤0.05; **=P≤0.005; ***=P≤0.0005. (F) 
IL-1α was measured in day 21 plasma samples from both WT and B27 groups. Error bars 
indicate mean ± SD of n=9-10 for B27 and n=3 for WT groups. Kruskal-Wallis test with 
Dunn's multiple comparisons test was used to assess the significance. **= P≤0.01. 
 
Figure 4. CD43
lo
 monocytes develop the highest number of osteoclasts in vitro. BMCs 
were collected from B7, B27 and WT rats and specific monocyte populations were sorted 
using flow cytometry. Sorted cells were cultured at the same density in pro-osteoclastogenic 
medium (50 ng/ml M-CSF and 50 ng/ml RANK-L) and after 7 days fixed and stained for 
TRAP. (A) Representative pictures of TRAP staining (purple staining) of the total BMCs and 
the different subpopulation analysed. Scale bar = 500µm (B) TRAP
+
 multinucleated (≥3 
nuclei) cells (TRAP
+
 MNCs) were quantified as osteoclasts. Bars show mean ± SD. n=3 for 
WT, B7, and B27, from 3 different experiments pooled together. 
 
Figure 5. Antibiotics reverse the BM monocyte/osteoclast phenotype of B27 animals. 
B27 and WT animals received 4 weeks of ABX or water (CTRL) and at day 26 non-
adherent-BMCs were collected and cultured in presence of 50 ng/ml M-CSF, 10 ng/ml 
RANK-L, and 50 ng/ml TNFα in triplicate wells. On day 4, medium was refreshed and on 
day 5 cells were fixed and stained for TRAP. Osteoclasts were quantified as TRAP
+
 MNCs 
(≥3 nuclei) from 4 digital pictures per well. (A) The number of TRAP
+
 MNCs deriving from 
culture of B27 and WT ABX and CTRL animals. Data in B27 derived from 2 different 
experiments pooled together for a total of n=7-8 for B27 and n=3 for WT. (B) Representative 
pictures show TRAP staining in a CTRL and ABX B27 cultures. Data were analysed with 
one-way ANOVA and Sidak’s multiple comparison test. *=P≤0.05. **=P≤0.005. 
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Supplemental Figure 1. Gating strategy for the identification of monocytes and 
monocyte subsets within the blood and BM. White cell fraction was collected from blood 
(A) and BM (B) of WT rats, stained for flow cytometry, and analysed. (A-B) Representative 
flow cytometry plots show the gating strategy used to identify monocyte subsets. Single 
DAPI
-
 cells were identified as live cells and further gated. Ig kappa (Igκ), CD90, and OX-33 
(CD45RA) were used to exclude B and T cells from the analysis. Polymorphonuclear cells 
(PMNs) and monocytes (MOs) were gated by their side scatter properties (SSC-A) and 
expression of CD172a. MOs (SSC
lo
CD172a
hi
) were further analysed by their expression of 
CD11b and CD43. (A) Within the blood two different populations were gated: 
CD11b
+
CD43
lo
 (or CD43
lo
) and CD11b
+
CD43
hi
 (or CD43
hi
). (B) CD43
hi 
and CD43
lo
 in the 
BM were gated based on the expression of CD172a. Numbers in the density plots indicates 
frequencies of the parent population.  
 
Supplemental Figure 2. TNFα/RANK-L synergism in osteoclastogenesis is enhanced in 
B27 animals. BMCs were collected from age matched WT, B7, and B27 rats and incubated 
for 2 days with 2.5 β-glycerol phosphate and 0.05 mg/ml L-ascorbic acid. On day 1 NA-
BMCs were collected and plated in the presence of 50 ng/ml M-CSF and 10 ng/ml RANK-L, 
and different concentrations of TNFα (10, 50 or 100 ng/ml). Cells were fixed and stained for 
TRAP on day 5. (A) Representative reconstructed pictures of TRAP stained cultures from a 
B7, and B27 NA-BMCs treated with varying TNFα concentrations. (B) Quantification of 
osteoclasts number (TRAP
+
 MNCs) from four pictures per well taken at 10X magnification. 
Bars show mean ± SD of an n=3. Data were analysed with 2way ANOVA and Sidak's 
multiple comparisons test. *= P≤0.05. **= P≤0.005. 
  
 
 
Figure 1. B27 rats have increased CD43lo monocytes in the bone marrow and blood. (A-F) The 
white fraction of cells was collected from WT, B7, and B27 blood and bone marrow (BM) and analysed via 
flow cytometry. (A) Representative density plots showing the expression of CD11b and CD43 of circulating 
blood monocytes (MOs; lin
-SSCloCD172a+) in WT and B27 animals. The experiment was repeated 3 times for 
a total of n=6 for each group; in (B) the percentage and in (C) the absolute numbers of CD43lo and CD43hi 
in WT, B7 and B27 determined. (D) BM was collected from WT, B7 and B27 rats and analysed for the 
expression of CD172a and CD43. Representative density plots show the distribution of BM MOs in B7 and 
B27 rats. (E) Percentages and (F) absolute numbers of the MO subsets in WT, B7 and B27 animals. 
Numbers were calculated from three different experiments pooled together for a total of n=5 for WT and 
n=6 for B7 and B27. Data were analysed using 2-way ANOVA with Tukey’s multiple comparisons test. 
*=P<0.05; **=P≤0.005. ***= P≤0.001. ****= P≤0.0001.  
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Figure 2. Antibiotics reduce ileitis and re-establish normal levels of CD43lo monocytes in B27 
animals. (A-F) B27 and WT animal received 4 weeks of antibiotics (ABX) or water (vehicle control, CTRL) 
and at day 26 the blood white cell fraction and bone marrow cells (BMCs) were collected and stained for flow 
cytometry. (A) Representative H&E staining sections of the ileum of ABX and water-treated (CTRL) WT or 
B27 rats. Tissue sections were visualised and digital images captured using an EVOS FL Auto Cell Imaging 
System with a 10X objective. Scale bars = 400 µm. (B) Quantification of villus to crypt ratio. For each 
sample the average of the length of villus and crypt was calculated on 2 different tissue sections. Error bars 
show mean ± SD of n=3-4 for ABX and n=2-3 for CTRL. (C) Representative flow cytometry plots showing 
the monocyte gating in CTRL and ABX within the blood. (D) Quantification of circulating CD43lo and CD43hi 
MOs in B27 and WT rats receiving ABX or water (CTRL). (E) Representative dot plots show the BM monocyte 
populations in CTRL and ABX B27 rats. (F) The quantification of CD43lo and CD43hi subsets. (D&F) Numbers 
were calculated from 3 different experiments pooled together using B27 (n=9 for B27-CTRL and n=12 for 
B27-ABX) and one experiment using WT rats (n=3). Data were analysed using Kruskal-Wallis test with 
Dunn’s post hoc test in (B) and one-way ANOVA in (D&F) with Sidak’s multiple comparison test. 
*=P≤0.05; **=P≤0.005; ***=P≤0.0005.  
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Figure 3. Antibiotics reduce CCL2 plasma levels in B27 rats. (A-B) CD43lo monocytes uptake CCL2 
and efficiently migrate toward CCL2 gradient. (A) Blood and BM cells were collected from WT rats, 
incubated with CCL2AF647 followed by staining for surface marker expression and flow cytometry analysis. 
The representative histograms show CCL2AF647 fluorescence of CD43lo and CD43hi MO subsets in blood and 
BM. The experiment used 3 different animals and showed comparable results. (B) BM was collected from a 
WT animal and total BMCs were placed in the top section of a bare filter trans-well. Increasing 
concentrations of recombinant rat CCL2 were used as chemo-attractant in the bottom section of the trans-
wells. After 3 hours, trans-migrated cells were collected, stained and quantified via flow cytometry. Data 
were analysed with 2-way ANOVA and Dunnett’s post-hoc test comparing each data set to the 0 ng/ml 
values. Data shown are from 1 experiment performed in triplicate. Bars show mean ± SD. *= P≤0.05; **= 
P≤0.01; ****= P≤0.0001. (C) Plasma was collected from B7 and B27 animals and CCL2 plasma levels 
quantified by ELISA. Data were analysed with Mann Whitney test. *= P≤0.05; n=6 for both B7 and B27 
samples. (D) Blood from B27 animals receiving the vehicle (CTRL) was collected twice a week for 4 weeks; 
numbers of CD43lo and CCL2 plasma levels were measured for each sample. Samples were collected from 2 
different experiments and results pooled. Correlation analysis was performed using Pearson r test. n=50. 
(E) Plasma was collected at different time points (day 1 to 26) from B27 and WT rats treated with ABX or 
water (CTRL) and CCL2 measured by ELISA. Plasma CCL2 of 3 different experiments pooled together in B27 
rats and 1 experiment using WT. Error bars shown mean ± SD. In B27-CTRL n=9; in B27-ABX n=12; in WT-
CTRL n=3; in WT-ABX n=3. Data were analysed using 2-way ANOVA and Sidak’s multiple comparison test 
for repeated measure. *=P≤0.05; **=P≤0.005; ***=P≤0.0005. (F) IL-1α was measured in day 21 plasma 
samples from both WT and B27 groups. Error bars indicate mean ± SD of n=9-10 for B27 and n=3 for WT 
groups. Kruskal-Wallis test with Dunn's multiple comparisons test was used to assess the significance. **= 
P≤0.01.  
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Figure 4. CD43lo monocytes develop the highest number of osteoclasts in vitro. BMCs were collected 
from B7, B27 and WT rats and specific monocyte populations were sorted using flow cytometry. Sorted cells 
were cultured at the same density in pro-osteoclastogenic medium (50 ng/ml M-CSF and 50 ng/ml RANK-L) 
and after 7 days fixed and stained for TRAP. (A) Representative pictures of TRAP staining (purple staining) 
of the total BMCs and the different subpopulation analysed. Scale bar = 500µm (B) TRAP+ multinucleated 
(≥3 nuclei) cells (TRAP+ MNCs) were quantified as osteoclasts. Bars show mean ± SD. n=3 for WT, B7, and 
B27, from 3 different experiments pooled together.  
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Figure 5. Antibiotics reverse the BM monocyte/osteoclast phenotype of B27 animals. B27 and WT 
animal received 4 weeks of ABX or water (CTRL) and at day 26 non-adherent-BMCs were collected and 
cultured in presence of 50 ng/ml M-CSF, 10 ng/ml RANK-L, and 50 ng/ml TNFα in triplicate wells. On day 4, 
medium was refreshed and on day 5 cells were fixed and stained for TRAP. Osteoclasts were quantified as 
TRAP+ MNCs (≥3 nuclei) from 4 digital pictures per well. (A) The number of TRAP+ MNCs deriving from 
culture of B27 and WT ABX and CTRL animals. Data in B27 derived from 2 different experiments pooled 
together for a total of n=7-8 for B27 and n=3 for WT. (B) Representative pictures show TRAP staining in a 
CTRL and ABX B27 cultures. Data were analysed with one-way ANOVA and Sidak’s multiple comparison test. 
*=P≥0.05. **=P≥0.005.  
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